Clinical Trial Search

Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons

Primary: Objective Response Rate (PR or CR) — 0 percentage of evalubale patients

Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…

Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…

Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants

Primary: Recruitment Rate (Percentage of Potentially Eligible Participants Who Were Enrolled to the Study) — 20.3 percentage of participants

Primary: HPV Identification — 95; 142; 78 biopsies

Primary: Tumor Response — 1; 7; 17; 34 participants

Primary: Number of Participants Who Scheduled or Completed Cervical Cancer Screening — 28; 21 Participants

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…

Primary: Number of Patients With Dose-limiting Toxicities, as Assessed by CTCAE v 4.0 — 0 Participants

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population) — 8; 7; 11; 6 participant

Primary: Progression-Free Survival — 64.7 percentage of patients

Primary: Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years — 55; 83; 149; 141 participants — p=0.029

Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months

Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants

Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants

Primary: Number of Participants Who Obtain or Self-Report Future Desire for Cervical Cancer Screening — 59; 71 Participants

Primary: Number of Participants Diagnosed With Cervical Epithelial Neoplasia Grade 2 or Worse — 12; 8 Participants

Primary: Pelvic Recurrence Rate at 3 Years — 2.17; 2.52 percentage of participants

Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants

Primary: Disease-free Survival (Percentage of Participants Alive Without Disease) — 86.4; 82.1; 76.2; 76.9 percentage of participants — p=0.56

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Number of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 — 56 Adverse Events

Primary: Number of Patients Completing the Protocol — 27 Participants

Primary: Human Papilloma Virus (HPV) Vaccine #1 Acceptance — 13; 12; 7; 3 Participants

Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…

Primary: Objective Tumor Response — 11.8 percentage